P/ 310-827-7707 | F/ 310-574-4002 | MAIL@PROSTATEONCOLOGY.COM
BY MARK SCHOLZ, MD When surgical margins are positive, several studies show that immediate radiation to the prostate fossa will lower the relapse rates and may slightly improve ten-year survival …
BY MARK SCHOLZ, MD The anatomical location of the prostate gland, situated within millimeters of the bladder and rectum, means that urologists are simply unable to cut a wide margin around …
BY MARK SCHOLZ, MD The American Urology Association meeting is the world’s largest urology meeting. The program is structured around the exposition of several thousand scientific presentations that are released in preliminary …
BY MARK SCHOLZ, MD There is a real danger that PSA screening will lead to overtreatment. The government, having studied this situation, has therefore recommended dropping PSA screening altogether. This proposal doesn’t …
BY MARK SCHOLZ, MD At the first ever Active Surveillance Convention, a conference I attended back in 2007, many experts openly bemoaned that the word “CANCER” profoundly overstates the significance …
BY MARK SCHOLZ, MD Avodart and Proscar are FDA-approved for treating urinary side effects from prostate enlargement. The generic name for Avodart is dutasteride; the generic name for Proscar is finasteride. These medications, …
BY MARK SCHOLZ, MD After sitting down with a new patient Tom, a charming 80-year-old man who was recently found to have a prostate nodule and a PSA elevated up to 50, …
BY MARK SCHOLZ, MD In Part One, I reviewed some of the background theories on how treating metastatic disease, when only a limited number of metastatic sites exist, might be beneficial, …
BY MARK SCHOLZ, MD Over the last 15 years or so, modern thinking about how to treat the early stages of prostate metastases has been changing. Various studies are showing …